DE69927987T2 - Hemmung von mit gewebetrauma verbundenen pathogenen prozessen - Google Patents

Hemmung von mit gewebetrauma verbundenen pathogenen prozessen Download PDF

Info

Publication number
DE69927987T2
DE69927987T2 DE69927987T DE69927987T DE69927987T2 DE 69927987 T2 DE69927987 T2 DE 69927987T2 DE 69927987 T DE69927987 T DE 69927987T DE 69927987 T DE69927987 T DE 69927987T DE 69927987 T2 DE69927987 T2 DE 69927987T2
Authority
DE
Germany
Prior art keywords
halofuginone
collagen
expression
inhibition
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69927987T
Other languages
German (de)
English (en)
Other versions
DE69927987D1 (de
Inventor
Mark Pines
Israel Vlodavsky
Arnon Nagler
Eli Hazum
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hadasit Medical Research Services and Development Co
Agricultural Research Organization of Israel Ministry of Agriculture
Original Assignee
Hadasit Medical Research Services and Development Co
Agricultural Research Organization of Israel Ministry of Agriculture
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hadasit Medical Research Services and Development Co, Agricultural Research Organization of Israel Ministry of Agriculture filed Critical Hadasit Medical Research Services and Development Co
Publication of DE69927987D1 publication Critical patent/DE69927987D1/de
Application granted granted Critical
Publication of DE69927987T2 publication Critical patent/DE69927987T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69927987T 1998-08-13 1999-08-13 Hemmung von mit gewebetrauma verbundenen pathogenen prozessen Expired - Fee Related DE69927987T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IL12579098 1998-08-13
IL12579098 1998-08-13
US13714599P 1999-06-01 1999-06-01
US137145P 1999-06-01
PCT/IL1999/000440 WO2000009070A2 (en) 1998-08-13 1999-08-13 Inhibition of pathogenic processes related to tissue trauma

Publications (2)

Publication Number Publication Date
DE69927987D1 DE69927987D1 (de) 2005-12-01
DE69927987T2 true DE69927987T2 (de) 2006-11-09

Family

ID=26323693

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69927987T Expired - Fee Related DE69927987T2 (de) 1998-08-13 1999-08-13 Hemmung von mit gewebetrauma verbundenen pathogenen prozessen

Country Status (8)

Country Link
EP (1) EP1109559B1 (https=)
JP (1) JP2002522462A (https=)
AT (1) ATE307586T1 (https=)
AU (1) AU756437B2 (https=)
CA (1) CA2340176A1 (https=)
DE (1) DE69927987T2 (https=)
ES (1) ES2255286T3 (https=)
WO (1) WO2000009070A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL143366A0 (en) * 2001-05-24 2002-04-21 Harasit Medical Res Services & Treatment of renal fibrosis
US20060258692A1 (en) * 2002-10-31 2006-11-16 Mark Pines Quinazolinone compositions for regulation of gene expression related to pathological processes
RU2243778C2 (ru) * 2003-02-18 2005-01-10 Московский городской научно-исследовательский институт скорой помощи им. Н.В. Склифосовского Способ лечения последствий травматического и интраоперационного повреждения тканей у больных с политравмой
AU2007238816B2 (en) * 2006-04-10 2012-12-06 President And Fellows Of Harvard College Methods for modulating formation and progression of cellulite
US8410120B2 (en) 2007-01-21 2013-04-02 Mark Pines Composition and method for treating or preventing skeletal muscle fibrosis
US9284297B2 (en) 2008-08-11 2016-03-15 President And Fellows Of Harvard College Halofuginone analogs for inhibition of tRNA synthetases and uses thereof
US20130323763A1 (en) 2011-02-10 2013-12-05 Sapporo Medical University Method for diagnosing acute lung injury
AU2013207796B2 (en) 2012-01-13 2017-04-27 President And Fellows Of Harvard College Halofuginol derivatives and their use in cosmetic and pharmaceutical compositions
WO2019237125A1 (en) 2018-06-08 2019-12-12 The General Hospital Corporation Inhibitors of prolyl-trna-synthetase

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3320124A (en) * 1964-07-20 1967-05-16 American Cyanamid Co Method for treating coccidiosis with quinazolinones
DE2934069A1 (de) * 1979-08-23 1981-03-12 Hoechst Ag, 6000 Frankfurt Mittel gegen theileriosen und seine verwendung.
JPH08510251A (ja) * 1993-05-07 1996-10-29 ビー マーゴリン、ソロモン 線維症の病変の修復と予防のための組成物および方法
CA2113229C (en) * 1994-01-11 1999-04-20 Mark Pines Anti-fibrotic quinazolinone-containing compositions and methods for the use thereof
IL110831A (en) * 1994-08-31 1998-12-27 Hadasit Med Res Service Pharmaceutical compositions containing quinazolinone derivatives for preventing restenosis
JPH0971586A (ja) * 1995-09-07 1997-03-18 Yamanouchi Pharmaceut Co Ltd 新規な二環性縮合イミダゾール誘導体
EP0956354B1 (en) * 1996-07-03 2009-01-14 Université de Liège Recombinant n-proteinase, and the production, methods and uses thereof
EP1806131A3 (en) * 1996-07-22 2007-08-01 Renovo Limited Use of sex steroid function modulators to treat wounds and fibrotic disorders
DE69716460T2 (de) * 1996-12-04 2003-06-26 Renovo Ltd., Manchester Wundheilung und behandlung von fibrose
US5852024A (en) * 1997-02-11 1998-12-22 Hadasit Treatment and prevention of adhesions
US6028075A (en) * 1997-02-11 2000-02-22 Pines; Mark Quinazolinone containing pharmaceutical compositions for prevention of neovascularization and for treating malignancies
DE19951702A1 (de) * 1999-10-27 2001-05-03 Aventis Pharma Gmbh Verwendung von 2-Amino-3,4-dihydro-chinazolinen zur Herstellung eines Medikaments zur Behandlung oder Prophylaxe von durch ischämischen Zuständen bewirkten Krankheiten

Also Published As

Publication number Publication date
ATE307586T1 (de) 2005-11-15
AU5191499A (en) 2000-03-06
WO2000009070A3 (en) 2000-10-19
WO2000009070A2 (en) 2000-02-24
ES2255286T3 (es) 2006-06-16
AU756437B2 (en) 2003-01-16
EP1109559B1 (en) 2005-10-26
JP2002522462A (ja) 2002-07-23
EP1109559A2 (en) 2001-06-27
DE69927987D1 (de) 2005-12-01
EP1109559A4 (en) 2002-05-08
CA2340176A1 (en) 2000-02-24

Similar Documents

Publication Publication Date Title
AT392081B (de) Verfahren zur herstellung eines arzneimittels zur behandlung von virusinfektionen
DE60003010T2 (de) Verwendung eines serenoa repens extraktes zur herstellung eines arzneimittels zur behandlung von krebserkrankungen der prostata
DE69428130T3 (de) Verwendung von bcl-2 zur herstellung von arzneimitteln zur therapeutischen behandlung und verhinderung von krankheiten
DE69829857T2 (de) Hypoxie-regulierte gene
DE19539861A1 (de) Verwendung von 4-Amino-4-(4-fluorbenzylamino)-1-ethoxy-carbonylaminobenzen zur Prophylaxe und Behandlung der Folgen der akuten und chronischen zerebralen Minderdurchblutung sowie neurodegenerativer Erkrankungen
DE69927987T2 (de) Hemmung von mit gewebetrauma verbundenen pathogenen prozessen
WO2006015560A1 (de) Immunmodulierendes mittel in verbindung mit chemotherapeutischen massnahmen
DE10059144A1 (de) Modulation der Transkription pro-inflammatorischer Genprodukte
DE69613984T2 (de) Für die protein-kinase a-spezifische modifizierte oligonukleotide und verfahren zur deren verwendung
DE69736243T2 (de) 2-CYCLOPENTEN-1-ON UND SEINE DERIVATE ALS INHIBITOREN VON NF-kappa B
DE10148828B4 (de) Modulation der Expression STAT-1-abhängiger Gene
DE69332702T2 (de) Verwendung der gensequenz eines promotors zur behandlung rheumatischer erkrankungen
US20070010538A1 (en) Inhibition of pathogenic processes related to tissue trauma
EP1368027B1 (de) Verwendung von tryptophan-derivaten zur spezifischen zytostatischen behandlung von serotonin-produzierenden tumoren
EP1605952B1 (de) Verwendung von 5-substituierten nukleosiden zur verstärkung der apoptotischen wirkung von zytostatika
DE3872749T2 (de) Anwendung von odc-inhibitoren, dacarbazin und interferon in der behandlung boesartiger melanome.
DE69835525T2 (de) Verminderungsregulation der genexpression durch kolorektale verabreichung von synthetischen oligonukleotiden
DE102008031036A1 (de) Dasatinib zur Anwendung in der Organtransplantation
EP1536840B1 (de) Formulierung zur einschleusung von nukleinsäuren in eukaryotischen zellen
Lescaudron et al. Effects of fetal forebrain transplants in ibotenic-injured nucleus basalis: an anatomical investigation
DE4442257A1 (de) Sparsomycin
DE60030754T2 (de) Potenzierung der wirksamkeit von sn-38-prodrogen
DE3844518A1 (de) Verwendung von aminochinolinen und aminopyridinen zur iontophoretischen behandlung maligner tumore
IL141408A (en) Compositions for treating cardiac fibrosis comprising halfuginone derivatives
CN115501223A (zh) 杜鹃素在制备抗脑缺血再灌注损伤药物中的应用

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee